Educational information, reviewed by Ryan Arvizo, FNP-C. Current as of September 2026. Not medical advice. Prices were read from the manufacturer’s page on 2026-09-26.
If you were getting compounded semaglutide from a large telehealth company and it stopped, you are in a group that grew fast in 2026. Here is what happened, what it means, and what you can do.
What changed
- The FDA moved to close the bulk route. On April 30, 2026 the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the list that lets outsourcing facilities compound from bulk ingredients. That is the route large-scale compounded programs relied on.
- The FDA sent warning letters. In early 2026 the agency warned 30 telehealth companies over claims that compounded GLP-1s were the same as approved products or that obscured who actually made them. A further group of letters followed in June.
- The biggest sellers changed course. In February 2026 Hims & Hers withdrew a compounded semaglutide pill after regulatory pushback, and in March it announced a partnership with Novo Nordisk under which it stopped advertising compounded semaglutide and began transitioning patients to brand-name Wegovy.
Our earlier guide on whether compounded semaglutide is still legal covers the background.
What it means for you
Mass-produced compounded semaglutide is going away. Two lawful paths remain:
- Brand-name medication, self-pay. Wegovy through the manufacturer’s own pharmacy is $149 per month for the lowest-dose pill, and $199 for the first two pen fills for new self-pay patients through December 31, 2026, then $349. Zepbound (tirzepatide) starts at $299 per month. A prescription and a provider are still required.
- Patient-specific compounding under Section 503A, prepared by a state-licensed pharmacy on an individual prescription when there is a documented clinical reason the commercial product does not fit you. This is narrower than before and is a provider decision.
What to do this week
- Do not buy from an unverified source. “Research use only” vials and unlicensed sellers are not made or tested for people.
- Do not stop or change your dose on your own. Talk to a provider about how to transition.
- Gather three things: your medication name and dose, the date of your last dose, and any recent labs.
- Book a provider evaluation. At BioPeakRx that is a free consult with a licensed provider who will tell you which path fits, including whether brand-name self-pay is the right answer for you. The $110 fee was removed, so there is no cost to get an answer.
How BioPeakRx handles it
Nothing is sold direct-to-cart. Anything prescribed comes from a state-licensed, FDA-registered U.S. pharmacy on your individual prescription. Compounded medications are not FDA-approved, and your provider will explain what that means before you decide. We track the regulatory status of these medications continuously, so the guidance you get reflects the rules as they are now.
Sources
- FDA, FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List (April 30, 2026)
- FDA, FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s
- FDA, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
- CNBC, Hims & Hers pulls copycat weight-loss pill after threats of legal action (February 7, 2026)
- Hims & Hers Health, Form 8-K press release on the Novo Nordisk partnership (March 2026)
- NovoCare, Wegovy self-pay pricing
- LillyDirect, Zepbound self-pay pricing
This information is educational and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Compounded medications are not FDA-approved. Treatments require evaluation by a licensed provider.